The Patent Finder

Kos Therapeutics, Inc.

10 patents currently held · Updated Nov 16, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Mar 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 16, 2026
    The maintenance fee for Amino acid derivatives containing a disulfanyl group in the form of an NEP and APN inhibitor for the prevention and treatment of trigeminal nerve pain (US 11,648,231) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
  • 1 fee due Mar 3, 2027
    The maintenance fee for Industrial process for the preparation of (5S, 10S)-10-benzyl-16-methyl-11, 14, 18-trioxo-15, 17, 19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium(E)-3-carboxyacrylate salt (US 10,399,936) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

PatentTitleStatus Expires Confidence
US 8,247,609Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,466,309Amino acid derivatives, method for preparing same, and therapeutic use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,247,608Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,131,681Aminophosphinic derivatives that can be used in the treatment of pain
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,703,747Aminophosphinic derivatives that can be used in the treatment of pain
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,388,129Mixed inhibitors of aminopeptidase N and neprilysin
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,399,936Industrial process for the preparation of (5S, 10S)-10-benzyl-16-methyl-11, 14, 18-trioxo-15, 17, 19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium(E)-3-carboxyacrylate salt
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,648,231Amino acid derivatives containing a disulfanyl group in the form of an NEP and APN inhibitor for the prevention and treatment of trigeminal nerve pain
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,391,710Method for the Industrial Preparation of the Disodium Salt of ((2S)-3-([1,1'-Biphenyl]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL) Methyl)propanoyl)-L-Alanine
In force
 · High confidence
In forceHigh confidence
US 12,753,149N-Formylhydroxylamines as Neprilysin (NEP) Inhibitors, in Particular as Mixed Aminopeptidase N (APN) and Neprilysin (NEP) Inhibitors
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 10: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited